Page 82 - Priority Review News Today

COPENHAGEN, Denmark--(BUSINESS WIRE)--Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell...

Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab

– Data showcase the potential of glofitamab and mosunetuzumab to address diverse patient needs – – Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pretreated large B-cell lymphoma – – 27-month follow-up data showed mosunetuzumab continued to induce high and durable responses in people with relapsed or refractory f...

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal...

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH) 1COMMODORE 3 is the first China-specific

Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment of Familial Exudative Vitreoretinopathy (FEVR) as a drug for “rare pediatric disease*”.

Pfizer said the Food and Drug Administration has agreed to a priority review of its candidate vaccine for respiratory syncytial virus for people 60 and older.

The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.